Fraxiparine

Fraxiparine is a medication containing Nadroparin Calcium, used for anticoagulation. It is administered via haemodialysis, intravenous, or subcutaneous routes. This product is manufactured by Viatris Healthcare Limited in the EU.

Fraxiparine is commonly used to prevent and treat blood clots. It is often prescribed for patients undergoing haemodialysis or those at risk of thromboembolic events. The medication works by inhibiting certain clotting factors in the blood, helping to maintain blood flow and reduce the risk of clots forming.

Common effects of Fraxiparine may include bruising, bleeding, and pain at the injection site. Some users might experience allergic reactions or changes in blood cell counts. It is important to monitor for any unusual symptoms and consult a healthcare provider if concerns arise.

Fraxiparine should be handled with care to avoid contamination. It is essential to follow proper administration techniques, especially when using the subcutaneous route. Patients with a history of bleeding disorders or those taking other anticoagulants should use this medication under medical supervision.

Fraxiparine may interact with other medications that affect blood clotting, such as aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs). Alcohol consumption should be moderated, as it can increase the risk of bleeding. Always inform healthcare providers about all medications being taken to avoid potential interactions.